Literature DB >> 95

[Luminescence study of the effect of temperature on the conformational state of fibrinogen].

S V Konev, M A Katibnikov, V A Bandarin, D Niamaa, E V Barkovskiĭ.   

Abstract

Results are presented of measuring fibrinogen fluorescence parameters in temperature range of 20-80 degrees C at different pH of the solution. It was found that the temperature increase from 20 to 40 degrees C for solutions with pH of 4,5-9,3 were not accompanied by the conformational changes of fibrinogen macromolecules. In the temperature range of 40-50 degrees C for neutral solutions conformational reconstruction of fibrinogen of undenatured character took place. Temperature increase above 50-55 degrees C brings about significant structural changes of fibrinogen molecule which are of denaturation nature.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 95

Source DB:  PubMed          Journal:  Biofizika        ISSN： 0006-3029


  4 in total

1.  The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.

Authors:  Laura C Coates; William Tillett; David Chandler; Philip S Helliwell; Eleanor Korendowych; Stuart Kyle; Iain B McInnes; Susan Oliver; Anthony Ormerod; Catherine Smith; Deborah Symmons; Nicola Waldron; Neil J McHugh
Journal:  Rheumatology (Oxford)       Date:  2013-07-25       Impact factor: 7.580

2.  Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.

Authors:  Bente Glintborg; Mikkel Ostergaard; Niels Steen Krogh; Martin Dehn Andersen; Ulrik Tarp; Anne Gitte Loft; Hanne M Lindegaard; Mette Holland-Fischer; Henrik Nordin; Dorte Vendelbo Jensen; Christian Holkmann Olsen; Merete Lund Hetland
Journal:  Arthritis Rheum       Date:  2013-05

3.  European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

Authors:  L Gossec; J S Smolen; C Gaujoux-Viala; Z Ash; H Marzo-Ortega; D van der Heijde; O FitzGerald; D Aletaha; P Balint; D Boumpas; J Braun; F C Breedveld; G Burmester; J D Cañete; M de Wit; H Dagfinrud; K de Vlam; M Dougados; P Helliwell; A Kavanaugh; T K Kvien; R Landewé; T Luger; M Maccarone; D McGonagle; N McHugh; I B McInnes; C Ritchlin; J Sieper; P P Tak; G Valesini; J Vencovsky; K L Winthrop; A Zink; P Emery
Journal:  Ann Rheum Dis       Date:  2011-09-27       Impact factor: 19.103

4.  The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.

Authors:  Chamaida Plasencia; Dora Pascual-Salcedo; Sara García-Carazo; Leticia Lojo; Laura Nuño; Alejandro Villalba; Diana Peiteado; Florencia Arribas; Jesus Díez; Maria Teresa López-Casla; Emilio Martín-Mola; Alejandro Balsa
Journal:  Arthritis Res Ther       Date:  2013-07-26       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.